.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,886,013

« Back to Dashboard

Claims for Patent: 5,886,013

Title: Antiviral composition
Abstract:The present invention relates to a pharmaceutical composition containing a compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H as antiviral agent.
Inventor(s): Rossignol; Jean-Francois (Clearwater, FL)
Assignee: Romark Laboratories, L.C. (Tampa, FL)
Application Number:08/847,130
Patent Claims: 1. A pharmaceutical composition, which comprises as active agent, compound A: ##STR15## and an effective amount of an antiviral agent selected from the group consisting of zalcitabine, acyclovir, and ganciclovir and a pharmaceutically acceptable carrier or diluent.

2. A method for treating viral infections comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition comprising as antiviral agent a mixture of compound A: ##STR16## and of compound B: ##STR17## the weight content of the said compound A with respect to the weight of said compounds A and B being from 1 to 20%.

3. A method for treating viral diseases comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition comprising as antiviral agent at least one of compound A: ##STR18## and compound B: ##STR19##

4. The method of claim 2, in which the weight content of the said compound A with respect to the weight of said compounds A and B is from 1 to 10%.

5. A method for treating viral diseases comprising administering to a subject in need of treatment an effective amount of compound A: ##STR20## as antiviral agent.

6. A method for treating viral diseases comprising administering to a subject in need of treatment an effective amount of a composition comprising compound A: ##STR21## and a further antiviral agent.

7. A method for treating Epstein Barr Virus diseases comprising administering to a subject in need of treatment an effective amount of a compound A: ##STR22## and/or a compound B: ##STR23## as antiviral agent.

8. A method for treating diseases caused by herpes viruses comprising administering to a subject in need of treatment an effective amount of compound A: ##STR24## as an agent against herpes viruses.

9. A method for treating liver diseases caused by viruses comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition which comprises as active agent compound A: ##STR25##

10. The method of claim 9, which comprises, as active agent, a mixture of compound A: ##STR26## and of compound B ##STR27##

11. The method of claim 10, in which the weight content of the said compound A with respect to the weight content of the said compounds A and B is from 1 to 20%.

12. A method for treating diseases caused by a virus selected from Varicella Zoster Virus, Human Cytomegalovirus and Murine Cytomegalovirus comprising administering to a subject in need of treatment a pharmaceutical composition which comprises as active agent, compound A: ##STR28##

13. The method of claim 12, wherein the pharmaceutical composition comprises, as active agent, a mixture of compound A: ##STR29## and of compound B ##STR30##

14. The method of claim 12, wherein the pharmaceutical composition the weight content of the said compound A with respect to the weight of said compounds A and B is between 1 and 20%.

15. A method for treating diseases caused by herpes virus selected from the group consisting of Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2) comprising administering to a subject in need of treatment an effective amount of a composition comprising compound A: ##STR31## and at least one agent selected from the group consisting of acyclovir, ganciclovir and zalcitabine.

16. The method of claim 15, wherein said HSV-1 is an acyclovir resistant HSV-1, and said HSV-2 is an acyclovir resistant HSV-2.

17. A method of treating Varicella Zoster Virus comprising administering a composition comprising an effective amount of compound A ##STR32## and an effective amount of nitazoxanide.

18. The method of claim 17, wherein said effective amount of compound A is 4%, and said effective amount of nitazoxanide is 96%.

19. A pharmaceutical composition which comprises as an active agent compound A ##STR33## and nitazoxanide, and at least one agent selected from the group consisting of zalcitabine, acyclovir and gancyclovir, and a pharmaceutically acceptable carrier or diluent.

20. A pharmaceutical composition which comprises as an active agent nitazoxanide and compound A in an effective amount.

21. The pharmaceutical composition of claim 20, wherein said amount is 4% and 96% for said nitazoxanide and said compound A, respectively.

22. A method for treating disease caused by trichomonas vaginalis comprising administering to a subject in need of treatment an effective amount of a composition comprising compound A ##STR34## and a pharmaceutically acceptable carrier or diluent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc